BH groups stress ‘system readiness’ as FDA weighs psychedelic treatments

Abstract

As federal regulators consider the future role of psychedelic therapies, behavioral health leaders are urging early planning around workforce development, clinical training and equitable access. The U.S. Food and Drug Administration (FDA) on Sept. 14 convened a four‐hour public hearing with federal partners to examine the potential therapeutic use of psychedelic drugs.